Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scientific basis for contact lens accessory downclassification questioned by ex-FDAer Charles Kyper.

This article was originally published in The Gray Sheet

Executive Summary

CONTACT LENS ACCESSORIES DOWNCLASSIFICATION PROPOSAL: SCIENTIFIC BASIS QUESTIONED by Charles Kyper, former director of reclassification and compliance in the Office of Device Evaluation, Center for Devices and Radiological Health, in April 20 comments to FDA. The agency's proposed rule to reclassify contact lens accessories, published in the April 1 Federal Register ("The Gray Sheet" April 8, In Brief), "neither summarizes, nor provides a bibliography of, the supporting safety and effectiveness information thereby not providing an opportunity for interested persons to support, or challenge, the proposed reclassification on the sufficiency of this supporting information," Kyper says. Kyper became a consultant at C.L. McIntosh when he left FDA in August 1994, and now heads up the consulting firm Kyper & Associates.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006055

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel